CL2019002019A1 - Nuevo compuesto heterocíclico, su método de preparación y composición farmacéutica que lo comprende. - Google Patents
Nuevo compuesto heterocíclico, su método de preparación y composición farmacéutica que lo comprende.Info
- Publication number
- CL2019002019A1 CL2019002019A1 CL2019002019A CL2019002019A CL2019002019A1 CL 2019002019 A1 CL2019002019 A1 CL 2019002019A1 CL 2019002019 A CL2019002019 A CL 2019002019A CL 2019002019 A CL2019002019 A CL 2019002019A CL 2019002019 A1 CL2019002019 A1 CL 2019002019A1
- Authority
- CL
- Chile
- Prior art keywords
- preparation
- pharmaceutical composition
- heterocyclic compound
- new heterocyclic
- arnetals
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/12—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1, 3, and 7, e.g. caffeine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
LA PRESENTE INVENCIÓN SE REFIERE A UN COMPUESTO HETEROCÍCLICO REPRESENTADO POR LA SIGUIENTE FÓRMULA QUÍMICA 1 QUE PUEDE USARSE PARA LA PREVENCIÓN O EL TRATAMIENTO DE ENFERMEDADES CAUSADAS POR LA ANORMALIDAD EN UNA ACTIVIDAD DE PRS (PROLIL–ARNT SINTETASA), O UNA DE SUS SALES FARMACÉUTICAMENTE ACEPTABLES; UN MÉTODO PARA SU PREPARACIÓN, Y UNA COMPOSICIÓN FARMACÉUTICA QUE LO COMPRENDE. EN LA FÓRMULA QUÍMICA 1, N, L, X1, X2 Y A SON COMO SE DEFINEN EN LA MEMORIA DESCRIPTIVA.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20170016971 | 2017-02-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2019002019A1 true CL2019002019A1 (es) | 2019-12-13 |
Family
ID=63107680
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2019002019A CL2019002019A1 (es) | 2017-02-07 | 2019-07-18 | Nuevo compuesto heterocíclico, su método de preparación y composición farmacéutica que lo comprende. |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US10981917B2 (es) |
| EP (1) | EP3580208B1 (es) |
| JP (1) | JP6785384B2 (es) |
| KR (1) | KR102084772B1 (es) |
| CN (1) | CN110191882B (es) |
| AR (1) | AR110963A1 (es) |
| AU (1) | AU2018218965B2 (es) |
| BR (1) | BR112019016291A2 (es) |
| CA (1) | CA3049643C (es) |
| CL (1) | CL2019002019A1 (es) |
| CO (1) | CO2019007834A2 (es) |
| DO (1) | DOP2019000193A (es) |
| EC (1) | ECSP19051409A (es) |
| ES (1) | ES2899665T3 (es) |
| HR (1) | HRP20211483T1 (es) |
| HU (1) | HUE056218T2 (es) |
| MA (1) | MA47469B1 (es) |
| MX (1) | MX2019009185A (es) |
| MY (1) | MY196538A (es) |
| PE (1) | PE20191477A1 (es) |
| PH (1) | PH12019501811A1 (es) |
| PL (1) | PL3580208T3 (es) |
| PT (1) | PT3580208T (es) |
| RS (1) | RS62541B1 (es) |
| RU (1) | RU2733384C1 (es) |
| SA (1) | SA519402180B1 (es) |
| SG (1) | SG11201906436VA (es) |
| SI (1) | SI3580208T1 (es) |
| TN (1) | TN2019000204A1 (es) |
| TW (4) | TWI700280B (es) |
| WO (1) | WO2018147626A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11168082B2 (en) * | 2017-05-15 | 2021-11-09 | The Regents Of The University Of Michigan | Pyrrolo[2,3-C]pyridines and related analogs as LSD-1 inhibitors |
| KR102346187B1 (ko) * | 2019-12-26 | 2021-12-31 | 울산과학기술원 | 디히드로퓨란 유도체 및 이의 합성 방법 |
| AU2022274469A1 (en) | 2021-05-13 | 2023-09-21 | Daewoong Pharmaceutical Co., Ltd. | Pharmaceutical composition for prevention or treatment of fibrosis |
| BR112023019668A2 (pt) | 2021-05-13 | 2023-11-28 | Daewoong Pharmaceutical Co Ltd | Composição farmacêutica para prevenir ou tratar fibrose |
| AR126552A1 (es) | 2021-07-23 | 2023-10-18 | Daewoong Pharmaceutical Co Ltd | Composición farmacéutica para prevenir o tratar la esclerosis sistémica |
| KR20230047910A (ko) * | 2021-10-01 | 2023-04-10 | 주식회사유한양행 | 바이사이클릭 융합환 유도체 또는 이의 염 및 이를 포함하는 약학 조성물 |
| WO2023113540A1 (ko) * | 2021-12-17 | 2023-06-22 | 주식회사 대웅제약 | (2r, 3s)-2-(3-(4,5-디클로로-1h-벤조[d]이미다졸-1-일)프로필)피페리딘-3-올의 신규한 산부가염 및 결정형 |
| KR20230092630A (ko) * | 2021-12-17 | 2023-06-26 | 주식회사 대웅제약 | (2R, 3S)-2-(벤조[d]이미다졸일프로필)피페리딘-3-올 유도체의 제조 방법 |
| WO2023239166A1 (ko) * | 2022-06-08 | 2023-12-14 | 주식회사 대웅제약 | 아르기나아제 저해제 및 이를 포함하는 약학적 조성물 |
| WO2024080777A1 (ko) * | 2022-10-12 | 2024-04-18 | 주식회사 대웅제약 | 신장염의 예방 또는 치료용 약학적 조성물 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8900719D0 (en) | 1989-01-13 | 1989-03-08 | Nycomed As | Compounds |
| DK0709384T3 (da) | 1994-10-31 | 1999-08-23 | Merck Patent Gmbh | Benzylpiperidinderivater med høj affinitet til aminosyrereceptorers bindingssteder |
| IL114951A (en) | 1995-08-15 | 1999-08-17 | Hadasit Med Res Service | Quinazolinone-containing pharmaceutical compositions for prevention of neovascularization |
| PT888353E (pt) | 1996-03-15 | 2003-11-28 | Novartis Ag | Novas n-7-heterociclil-pirrolo¬2,3-d|pirimidinas e sua aplicacao |
| CN1333028C (zh) * | 1999-08-20 | 2007-08-22 | Csl硅树脂公司 | 用作防腐蚀涂层的单组分有机聚硅氧烷橡胶组合物 |
| BR0208105A (pt) | 2001-03-15 | 2004-03-09 | Astrazeneca Ab | Inibidores de metaloproteinase |
| US7307088B2 (en) * | 2002-07-09 | 2007-12-11 | Amgen Inc. | Substituted anthranilic amide derivatives and methods of use |
| DK1883451T3 (da) | 2005-04-13 | 2011-03-14 | Neuraxon Inc | Substituerede indolforbindelser med NOS-hæmmende virkning |
| US20080269240A1 (en) | 2005-09-22 | 2008-10-30 | Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan | Novel Adenine Compound |
| SI2125792T1 (sl) | 2007-02-19 | 2011-03-31 | Glaxosmithkline Llc | Purinski derivati kot imunomodulatorji |
| SG193149A1 (en) * | 2008-08-11 | 2013-09-30 | Glaxosmithkline Llc | Novel adenine derivatives |
| WO2010019210A2 (en) * | 2008-08-11 | 2010-02-18 | President And Fellows Of Harvard College | Halofuginone analogs for inhibition of trna synthetases and uses thereof |
| US20130338201A1 (en) | 2009-11-02 | 2013-12-19 | Ahr Pharmaceuticals, Inc. | Method of Cancer Treatment with 2-(1H-Indole-3-Carbonyl)-Thiazole-4-Carboxylic Acid Methyl Ester |
| US20150086627A1 (en) | 2012-03-29 | 2015-03-26 | Halo Therapeutics, Llc. | Dosage forms of halofuginone and methods of use |
| WO2014145576A2 (en) | 2013-03-15 | 2014-09-18 | Northwestern University | Substituted pyrrolo(2,3-d)pyrimidines for the treatment of cancer |
| NZ727715A (en) * | 2014-06-23 | 2017-09-29 | Dae Woong Pharma | Novel heterocyclic compounds having prs enzyme inhibitory effect |
| KR102277538B1 (ko) * | 2015-06-08 | 2021-07-14 | 주식회사 대웅제약 | 신규한 헤테로 고리 화합물, 이의 제조 방법 및 이를 포함하는 약학적 조성물 |
-
2018
- 2018-02-06 AR ARP180100277A patent/AR110963A1/es unknown
- 2018-02-07 HU HUE18750794A patent/HUE056218T2/hu unknown
- 2018-02-07 WO PCT/KR2018/001625 patent/WO2018147626A1/en unknown
- 2018-02-07 RS RS20211375A patent/RS62541B1/sr unknown
- 2018-02-07 SI SI201830416T patent/SI3580208T1/sl unknown
- 2018-02-07 JP JP2019542437A patent/JP6785384B2/ja active Active
- 2018-02-07 PT PT187507942T patent/PT3580208T/pt unknown
- 2018-02-07 TW TW108107266A patent/TWI700280B/zh active
- 2018-02-07 MX MX2019009185A patent/MX2019009185A/es unknown
- 2018-02-07 CN CN201880006571.2A patent/CN110191882B/zh active Active
- 2018-02-07 BR BR112019016291A patent/BR112019016291A2/pt active Search and Examination
- 2018-02-07 TN TNP/2019/000204A patent/TN2019000204A1/en unknown
- 2018-02-07 PE PE2019001462A patent/PE20191477A1/es unknown
- 2018-02-07 PL PL18750794T patent/PL3580208T3/pl unknown
- 2018-02-07 CA CA3049643A patent/CA3049643C/en active Active
- 2018-02-07 MA MA47469A patent/MA47469B1/fr unknown
- 2018-02-07 EP EP18750794.2A patent/EP3580208B1/en active Active
- 2018-02-07 TW TW107104338A patent/TWI694070B/zh active
- 2018-02-07 MY MYPI2019004122A patent/MY196538A/en unknown
- 2018-02-07 KR KR1020180015091A patent/KR102084772B1/ko active IP Right Grant
- 2018-02-07 AU AU2018218965A patent/AU2018218965B2/en active Active
- 2018-02-07 HR HRP20211483TT patent/HRP20211483T1/hr unknown
- 2018-02-07 SG SG11201906436VA patent/SG11201906436VA/en unknown
- 2018-02-07 ES ES18750794T patent/ES2899665T3/es active Active
- 2018-02-07 TW TW110116961A patent/TWI782525B/zh active
- 2018-02-07 RU RU2019124878A patent/RU2733384C1/ru active
- 2018-02-07 US US16/477,575 patent/US10981917B2/en active Active
- 2018-02-07 TW TW109107089A patent/TWI772759B/zh active
-
2019
- 2019-07-08 SA SA519402180A patent/SA519402180B1/ar unknown
- 2019-07-17 EC ECSENADI201951409A patent/ECSP19051409A/es unknown
- 2019-07-18 CL CL2019002019A patent/CL2019002019A1/es unknown
- 2019-07-22 CO CONC2019/0007834A patent/CO2019007834A2/es unknown
- 2019-07-24 DO DO2019000193A patent/DOP2019000193A/es unknown
- 2019-08-06 PH PH12019501811A patent/PH12019501811A1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2019002019A1 (es) | Nuevo compuesto heterocíclico, su método de preparación y composición farmacéutica que lo comprende. | |
| CO2021005987A2 (es) | Compuestos de anillo fusionado | |
| ECSP19052302A (es) | Derivados de benzooxazol como inmunomoduladores | |
| CO2018007528A2 (es) | Compuestos heterocíclicos como inmunomoduladores | |
| BR112020008817B8 (pt) | Compostos moduladores da via de estresse integrada | |
| CL2017002066A1 (es) | Proteasas de cisteína | |
| BR112018067538A2 (pt) | inibidores de ire1-alfa de pequenas moléculas | |
| BR112018068341A2 (pt) | 6-hidróxi-4-oxo-1,4-di-hidropirimidina-5-carboxamidas como agonistas de apj | |
| MD3464249T2 (ro) | Derivați carbonucleozidici substituiţi utili în calitate de agenți anticanceroşi | |
| CL2018000596A1 (es) | Nuevos compuestos bicíclicos como inhibidores de la atx | |
| EA201790271A1 (ru) | Ингибиторы гликозидазы | |
| BR112017003312A2 (pt) | compostos de indazol como inibidores de fgfr quinase, preparação e uso dos mesmos | |
| UY35821A (es) | Compuesto heterocíclico | |
| CO2018005954A2 (es) | Compuestos heteroaromáticos como inhibidores de btk | |
| BR112016018062A8 (pt) | compostos terapêuticos, composição farmacêutica e usos | |
| CO2017001528A2 (es) | Compuestos novedosos de pirimidina sustituidos | |
| CO2017001506A2 (es) | Compuestos novedosos de pirimidina sustituidos | |
| CL2019000476A1 (es) | Compuestos de heteroarilcarboxamida como inhibidores de ripk2. | |
| BR112018014590A2 (pt) | formulações/composições compreendendo um inibidor de btk | |
| BR112017010311A2 (pt) | 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139 | |
| AR109022A1 (es) | Mezclas activas como plaguicidas | |
| ECSP20023626A (es) | Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3 | |
| CO2021001849A2 (es) | Nuevo derivado de amina heterocíclico y composición farmacéutica que lo comprende | |
| DOP2020000077A (es) | Nuevo derivado de fenilpiridina y composición farmacéutica que lo contiene | |
| CL2017002229A1 (es) | Inhibidores de bace1. |